Domestic MedTech gets shot in the arm with First Fund launched

AMTZ partners with MedArtha Capital to accelerate Innovation, Research and Manufacturing in Medical Devices Domain

Mumbai: India’s medical technology sector received a major boost with the launch of a dedicated MedTech Capital fund, aimed at accelerating innovation, research, and manufacturing in the country’s growing medical device ecosystem.

The platform, created through a partnership between Andhra Pradesh MedTech Zone (AMTZ) and MedArtha Capital, India’s MedTech Capital Fund, was unveiled in Mumbai by Union Minister for Commerce and Industry Hon’ble Shri Piyush Goyal. The initiative provides growth capital and strategic support to emerging medical device companies, strengthens domestic manufacturing, and aims to create multiple globally competitive MedTech leaders.

Speaking at the launch, Shri Piyush Goyal described India’s MedTech sector as a “sunrise opportunity,” citing the country’s expanding talent pool and rising preventive healthcare awareness.

“India’s growing talent pool and rising preventive health awareness make MedTech a true sunrise opportunity. Platforms like this help bridge innovation and capital, enabling startups to scale, advance research, and strengthen manufacturing capabilities across the medical technology value chain,” Mr Goyal added.

Ganesh Sabat, Managing Partner of MedArtha Capital, said: “Scaling large, global medical technology companies requires the right capital, deep domain expertise, and access to specialized manufacturing infrastructure like AMTZ. MedArtha Capital is an operator-led investment platform that works closely with entrepreneurs to build globally competitive medical device companies from India.”

Dr Jitendra Sharma, MD & Founder CEO of AMTZ, added: “At AMTZ we have seen first-hand the innovation emerging from Indian MedTech entrepreneurs. Platforms like MedArtha Capital can play a pivotal role in building the next generation of global medical technology companies from India. With strong engineering, clinical expertise, and cost-efficient manufacturing, India has the potential to produce globally significant medical device companies.”

The launch also featured a high-level panel discussion emphasizing the importance of collaboration between investors, innovators, manufacturers, and policymakers in building a self-reliant, globally competitive MedTech ecosystem. The session was moderated by Mr Niraj Shah, Executive Editor at NDTV, and Ganesh Sabat, Managing Partner, MedArtha Capital, with distinguished panellists including Ms Swati Bansal, from the National Investment and Infrastructure Fund, Mr Bhargav Kotadia MD and CEO of SMT, and Mr Abhishek Kabra, Managing Director at Samara Capital.

As global demand for medical technologies grows, India is well-positioned to become a hub for high-quality, cost-effective medical devices, combining capital, infrastructure, and expertise to reduce imports and create globally competitive MedTech companies.

Related Posts

Medicines that cure Us are making Our Environment Sick

Antimicrobial Resistance Campaigner makes a Fervent Appeal for Safe Disposal of Leftover Medicines New Delhi: We invariably worry about what might be the side effects of medicines on our body…

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

National Organ Transplant Games2026 set World Record in Talkatora Indoor Stadium New Delhi: The National Organ Transplant Games began on a high note in Talkatora Indoor Stadium on November 1,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

Stents to syringes: Serious harm reports surge, but makers remain unnamed

Stents to syringes: Serious harm reports surge, but makers remain unnamed

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

Medicines that cure Us are making Our Environment Sick

Medicines that cure Us are making Our Environment Sick